Return to Results

Dose-Ranging Study in Patients With COPD

new search

Trial Conditions
  • COPD
What is the purpose of this trial?

The trial is designed to identify an appropriate dose of QAB149 for delivery via a multiple dose inhaler for use in the COPD Phase III program.

Date & Status

Completed

Who can Participate?

Eligibility

Ages:
40  - 75 

Gender:
Both

Eligibility

Inclusion Criteria:

- Diagnosis of COPD

- Age 40-75 years

- Smoking history

Exclusion Criteria:

- Other serious disease

- Allergy to QAB149

- Respiratory tract infection

Gender: Both
Steward Physician(s)
  • Novartis East Hanover
Trial Interventions
Drug
  • QAB149
Physician Researcher

Investigator Name:

  • Novartis East Hanover

Other Information

Sponsor: Novartis Pharmaceuticals
Phase: Phase 2
Trial ID: NCT00098228
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions